October 25, 2024 10:36 AM EDT
News Briefing

En­Gene’s $60M PIPE; Ab­b­Vie to de­vel­op neu­ropsy­chi­atric drugs with Gedeon Richter

ENDPOINTS

Plus, news about Tec­ton­ic Ther­a­peu­tic, Mol­e­c­u­lar Part­ners and Ar­cus Bio­sciences:

En­Gene snags $60M: The Boston and Mon­tre­al gene ther­a­py biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times